These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 18555813

  • 1. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
    Klipping C, Duijkers I, Trummer D, Marr J.
    Contraception; 2008 Jul; 78(1):16-25. PubMed ID: 18555813
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [Abstract] [Full Text] [Related]

  • 3. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L, Kunz M, Marr J.
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [Abstract] [Full Text] [Related]

  • 4. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure.
    Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N.
    Arch Gynecol Obstet; 2009 Aug; 280(2):255-61. PubMed ID: 19125264
    [Abstract] [Full Text] [Related]

  • 5. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM, Dietze P, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P.
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [Abstract] [Full Text] [Related]

  • 6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 7. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H.
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [Abstract] [Full Text] [Related]

  • 8. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Gerlinger C, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
    Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA.
    Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
    Rossmanith WG, Wirth U, Gasser S, Thun B, Steffens D.
    Zentralbl Gynakol; 1997 Dec; 119(11):538-44. PubMed ID: 9480608
    [Abstract] [Full Text] [Related]

  • 13. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Niknian M, Shulman LP, Lynen R.
    Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
    Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R.
    Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.